Meta-analysis of Association between Newer Glucose-Lowering Drugs and Risk of Parkinson's Disease.

ABSTRACT:

Background

The association between newer classes of glucose-lowering drugs (GLDs) and the risk of Parkinson's disease (PD) remains unclear.

Objective

The aim was to examine the effect of newer GLDs on the risk of PD through a meta-analysis of randomized outcome trials.

Methods

The methods included randomized placebo-controlled outcome trials that reported PD events associated with three newer classes of GLDs (ie, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, and sodium-glucose co-transporter-2 inhibitors) in participants with or without type 2 diabetes. The pooled odds ratio (OR) and 95% confidence interval (CI) were estimated using Peto's method.

Results

The study included 24 trials involving 33 PD cases among 185,305 participan

SUBMITTER: Tang H 

PROVIDER: S-EPMC10654811 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature